Director Jason Aryeh filed a Form 144 notice of proposed sale on November 4, 2026, disclosing plans to sell 282 shares of Ligand Pharmaceuticals Inc. Class B common stock through Wells Fargo Clearing Services.
Key Highlights
- Proposed sale: 282 shares of Class B common stock, with an aggregate market value of $90,225.50, according to the filing.
- Approximate sale date: November 4, 2026, executed through Wells Fargo Clearing Services in St. Louis, Missouri.
- Original acquisition: The 282 shares were acquired via secondary market purchase on May 14, 2019, for cash consideration.
- Recent prior sales: The filing discloses sales of 1,209 shares for $385,185.47 and 202 shares for $64,738.00, both on October 30, 2026, and 700 shares for $221,595.09 on November 2, 2026.
- Shares outstanding: The filing states 20,002,986 shares of Class B common stock outstanding.
- Filer's role: Jason Aryeh is identified as a Director of Ligand Pharmaceuticals Inc. (NASDAQ:LGND).
Jason Aryeh's Proposed Class B Share Sale at Ligand Pharmaceuticals
According to the Form 144 notice filed on November 4, 2026, Ligand Pharmaceuticals Inc. director Jason Aryeh intends to sell 282 shares of the company's Class B common stock. The filing lists an aggregate market value of $90,225.50 for the proposed sale and identifies the executing broker as Wells Fargo Clearing Services, located at 1 North Jefferson Avenue, St. Louis, Missouri 63103.
The filing discloses that the 282 shares subject to the proposed sale were originally acquired through a secondary market purchase on May 14, 2019, with payment made in cash. A remarks field in the filing states that "shares were acquired between 05/14/2019 to 07/30/2019." Ligand Pharmaceuticals is headquartered at 3911 Sorrento Valley Blvd, Suite 110, San Diego, California 92121, and its shares are listed on the Nasdaq exchange.
The filing also reports Aryeh's sales during the three months preceding the notice. On October 30, 2026, the filing records two separate transactions: 1,209 shares sold for gross proceeds of $385,185.47 and 202 shares sold for gross proceeds of $64,738.00. On November 2, 2026, an additional 700 shares were sold for gross proceeds of $221,595.09. All prior sales are listed under Ligand Pharmaceuticals, Inc. securities. The filing does not indicate whether a Rule 10b5-1 written trading plan is in place.
What Was Disclosed
Director Jason Aryeh filed a Form 144 disclosing the proposed sale of 282 Class B common shares of Ligand Pharmaceuticals Inc. valued at $90,225.50, along with three prior sales totaling 2,111 shares between October 30 and November 2, 2026.



Please wait processing your request...